Users Discontinuing Weight-Loss Jabs Put On Weight Four Times Faster Compared to Those on Conventional Diets

Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who halt traditional diet and exercise regimens.

Findings released in a leading medical journal demonstrates that while overweight individuals frequently drop about a fifth of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.

"People buying these drugs should be cognizant of the danger of quick weight regain when the medication concludes," cautioned researcher Dr. Susan Jebb.

That rate of regain means a reversion to starting weight within about 18 months.

Weighing Treatments

The research, which reviewed dozens of studies involving over 9,000 of participants, compared the outcomes of these new drugs with older methods.

The team point out that people who lose weight through diet and exercise typically experience a more gradual weight regain—around 0.1 kg a month—post-intervention.

Understanding the Quick Regain

Experts believe the mechanism of the injections is key to understanding the accelerated regain.

These medications mimic a natural hormone called glucagon-like peptide-1, which controls appetite.

"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.

"Stopping of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating far more likely."

An Ongoing Disease?

The NHS recommend the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.

Professionals say that, due to the significant potential of relapse, the therapy should be considered ongoing.

This perspective is reinforced by pharmaceutical companies, who note that the findings "emphasize the chronic character of obesity," comparing it to managing diseases like hypertension.

Patient Accounts

People who have stopped the jabs describe a intense resurgence of appetite.

"It was like a switch that goes on and I was suddenly starving," described a patient.

This challenge is compounded if patients have not developed permanent dietary or behavioural modifications during treatment.

Growing Use

Survey data suggest that a significant number of people in the UK have tried these injections in the past year, with interest continuing to grow.

• Adoption is more common among females compared to men.
• The 40s and 50s age group shows the highest usage rates.
• A large proportion access the drugs through private healthcare rather than the NHS.

In conclusion, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on ongoing behavioural changes.